Get the Stockscreener App
1.74
0.57%
-0.01
Pre-market:
1.90
0.16
+9.20%
Tempest Therapeutics Inc stock is traded at $1.74, with a volume of 200.34K.
It is down -0.57% in the last 24 hours and down -25.32% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$1.75
Open:
$1.76
24h Volume:
200.34K
Relative Volume:
1.44
Market Cap:
$23.46M
Revenue:
-
Net Income/Loss:
$-36.05M
P/E Ratio:
-0.1722
EPS:
-10.1029
Net Cash Flow:
$-33.40M
1W Performance:
-19.44%
1M Performance:
-25.32%
6M Performance:
-62.62%
1Y Performance:
-67.49%
1-Day Range:
$1.6549
$1.7899
1-Week Range:
$1.6549
$2.30
52-Week Range:
$1.20
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
1.74 | 23.46M | 0 | -36.05M | -33.40M | -10.10 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Angel Matthew, CEO and president, buys Tempest Therapeutics shares for $500k - Investing.com Australia
Tempest Therapeutics Insider Bought Shares Worth $500,001, According to a Recent SEC Filing - Moomoo
Matthew Angel’s 37.4% Tempest (NASDAQ: TPST) stake tied to asset deal, private placement - Stock Titan
Factor Bioscience tied to Tempest (NASDAQ: TPST) CEO buys 231,482 shares - Stock Titan
Downgrade Watch: Can Tempest Therapeutics Inc reach all time highs this yearRate Hike & Daily Profit Focused Screening - baoquankhu1.vn
Aug Macro: Will Tempest Therapeutics Inc stock recover after earningsMarket Trend Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn
TPST Q4'25 Earnings: revenue estimate is 0 USD - TradingView
2.26 out - Moomoo
Tempest Therapeutics (TPST) Projected to Post Quarterly Earnings on Wednesday - Defense World
Tempest Therapeutics raises $2 million in private placement By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Tempest Therapeutics Announces $2 Million Private Placement and Securities Purchase Agreement with Institutional and Strategic Investors - Minichart
Tempest Therapeutics Announces Private Placement Financing Agreement - TipRanks
Tempest Therapeutics Raises $2.0 Million in Private Placement With Warrants Priced at $2.16 - TradingView
Tempest Therapeutics (Nasdaq: TPST) details $2.0 million private placement deal - Stock Titan
Tempest Therapeutics Announces Up To $6 Million Private Placement - Bitget
Cancer drug developer Tempest lines up up to $6M in funding - Stock Titan
Tempest Therapeutics Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Technical Analysis: Is Tempest Therapeutics Inc exposed to political risk2026 Growth vs Value & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Final Week: Is Tempest Therapeutics Inc stock a value trap2026 Retail & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Is Tempest Therapeutics Inc stock a value trapWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn
Whats the MACD signal for Tempest Therapeutics IncMarket Volume Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn
Tempest Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US87978U2078 - marketscreener.com
Tempest Therapeutics, Inc. announced that it expects to receive $2 million in funding - marketscreener.com
Aug Fed Impact: Is Tempest Therapeutics Inc gaining market shareCEO Change & Safe Entry Point Identification - baoquankhu1.vn
Exit Recap: Is Tempest Therapeutics Incs growth already priced in2026 Reactions & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 - Bitget
Tempest Therapeutics Inc. (referred to as Tempest) recently disclosed a strategic collaboration regarding its core candidate drug Tpst-2003. - Bitget
Growth Review: Is Tempest Therapeutics Incs growth already priced in2026 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Growth Value: Whats the outlook for Tempest Therapeutics Incs sectorWeekly Stock Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
Earnings Recap: Is Tempest Therapeutics Inc stock a value trap2025 EndofYear Setup & Smart Swing Trading Techniques - baoquankhu1.vn
IPO Launch: Is AMBIWS a strong candidate for buy and hold2025 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn
TPST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tempest Therapeutics, Inc. (TPST) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Tempest Therapeutics, Inc.Common Stock (NQ: TPST - FinancialContent
Tempest Therapeutics reports complete response in myeloma trial By Investing.com - Investing.com Australia
EX-99.1 - SEC.gov
Tempest Therapeutics reports complete response in myeloma trial - Investing.com
Tempest Therapeutics Advances TPST-2003 CAR-T with Strong Data - TipRanks
Tempest reports 100% ORR in evaluable TPST-2003 patients, plans U.S. registrational study in 2026 - TradingView
Tempest Therapeutics (TPST) reveals 100% response in TPST-2003 multiple myeloma study - Stock Titan
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - Bitget
Tempest Announces Interim Results from Ongoing REDEEM-1 - GlobeNewswire
Why Tempest Therapeutics Inc. stock could outperform in 2025Weekly Profit Recap & Free Community Supported Trade Ideas - mfd.ru
How Tempest Therapeutics Inc. stock reacts to global recession fearsMarket Sentiment Report & AI Enhanced Execution Alerts - mfd.ru
Is Tempest Therapeutics Inc.’s growth already priced inBuy Signal & Daily Oversold Bounce Ideas - mfd.ru
What catalysts could drive Tempest Therapeutics Inc. stock higher2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru
Will Tempest Therapeutics Inc. stock recover after earningsM&A Rumor & Advanced Swing Trade Entry Plans - mfd.ru
TPST Should I Buy - Intellectia AI
How cyclical is Tempest Therapeutics Inc.’s revenue streamEarnings Performance Report & Smart Swing Trading Techniques - mfd.ru
Tempest Therapeutics Highlights Partner-Funded CAR-T Oncology Pipeline - The Globe and Mail
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):